The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of erdafitinib in adults with advanced solid tumors and non-prespecified fibroblast growth factor receptor mutations in the phase 2 RAGNAR trial: Exploratory cohort.
 
Iwona A. Lugowska
Honoraria - Agenus; Amgen; AstraZeneca; BeiGene; BMS; Celon Pharma; Cullinan Oncology; Jacobio; Janssen; Loxo; Macrogenics; Menarini; MSD; Pfizer; Rhizen Pharmaceuticals; ROCHE; Sanofi; Sanofi; Takeda
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AGENUS (Inst); ROCHE (Inst)
Travel, Accommodations, Expenses - BMS
 
Martin H. Schuler
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen-Cilag; MSD; Roche; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; MSD; Novartis; Roche; Sanofi; Tacalyx
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen; Loxo/Lilly; Merck KGaA; MSD Oncology; MSD Oncology (Inst); Pfizer (Inst); Pfizer/EMD Serono; Roche; Roche (Inst); Seagen; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Omar Carranza
Honoraria - Janssen
Consulting or Advisory Role - Merck Serono
Speakers' Bureau - janssen
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Raffo
 
Gopa Iyer
Consulting or Advisory Role - Bicycle Therapeutics; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Speakers' Bureau - Gilead Sciences; Lynx Group
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Toshihiko Doi
Honoraria - Daiichi Sankyo
Consulting or Advisory Role - A2 Healthcare; A2 Healthcare; Boehringer Ingelheim; Chugai Pharma; Gilead Sciences; Janssen; Kaken Pharmaceutical; Kyowa Hakko Kirin; Mitsubishi Tanabe Pharma; NanoCarrier; Noil-Immune Biotech; Noil-Immune Biotech; Oncolys BioPharma; Otsuka; PRA Health Sciences; Rakuten Medical; SHIONOGI; Sumitomo Pharma; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Janssen (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); PRA Health Sciences (Inst); RIN Institute (Inst); SHIONOGI (Inst); Taiho Pharmaceutical (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Josep Tabernero
Stock and Other Ownership Interests - 1TRIALSP; Alentis Therapeutics; Oniria Therapeutics; Pangaea Oncology
Consulting or Advisory Role - Alentis Therapeutics; AstraZeneca; AVEO; Boehringer Ingelheim; Cardiff Oncology; CARsgen Therapeutics; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; hC Bioscience Inc; Ikena Oncology; Immodulon Therapeutics; Inspirna; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Scorpion Therapeutics; Seagen; Servier; Sotio; Taiho Pharmaceutical; Takeda Pharmaceuticals International AG; Tolremo
Other Relationship - Imedex/HMP; Medscape; Peerview; Physicans' Education Resource
 
David A. Reardon
Stock and Other Ownership Interests - Anheart Therapeutics; Bionaut Labs
Honoraria - Advantagene; Agenus; Anheart Therapeutics; Avita Biomedical, Inc.; Bayer; Blue Rock Therapeutics; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CeCaVa; Chimeric Therapeutics; Deciphera; DelMar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Genentech/Roche; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kintara Therapeutics; KIYATEC; Medicenna; Merck; Merck KGaA; Monteris Medical; NEUVOGEN; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics; Sumitono Dainippon Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Vivacitas Oncology; Y-mAbs Therapeutics
Consulting or Advisory Role - Advantagene; Agenus; Agios; Anheart Therapeutics; Avita Biomedical; Bayer; Blue Rock Therapeutics; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CeCava; Chimeric Therapeutics; Deciphera; Delmar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Genentech/Roche; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kiyatec; Medicenna; Merck; Merck KGaA; NEUVOGEN; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics; Sumitomo Dainippon Pharma Oncology; Taiho Pharmaceutical; Vivacitas Oncology
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Asvattha Therapeutics (Inst); Celldex (Inst); EMD Serono (Inst); Enterome (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); InSightec (Inst); Merck (Inst); NeoTX (Inst); Novartis (Inst); Omniox
 
Christophe Massard
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; BMS; Celgene; Debiopharm Group; Faron Pharmaceuticals; Faron Pharmaceuticals; Faron Pharmaceuticals; Faron Pharmaceuticals; Faron Pharmaceuticals; Genentech/Roche; INNATE PHARMA; IPSEN; Janssen; Lilly; MSD; Novartis; ORION; Pfizer; PharmaMar; Sanofi; Taiho Pharmaceutical
 
Dirk Arnold
Employment - Asklepios Kliniken
Honoraria - Amgen; AstraZeneca; Boston Scientific; Bristol-Myers Squibb; Eisai Europe; Gilead Sciences; GlaxoSmithKline; Ipsen; Janssen Oncology; Merck Serono; Merck Sharp and Dome; Pierre Fabre; Sanofi/Regeneron; Seagen; SERVIER; Sirtex Medical; Takeda; TERUMO; Viatris
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck Serono; MSD Oncology
Research Funding - Oncolytics (Inst)
Travel, Accommodations, Expenses - Boston Scientific
(OPTIONAL) Uncompensated Relationships - Deputy Editor Clin Colorectal Cancer; ESMO; ESMO Open
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Consulting or Advisory Role - Celularity; Guardant Health; Sanofi
Speakers' Bureau - BMS; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
 
Helen Winter
Speakers' Bureau - Bristol-Myers Squibb; GlaxoSmithKline; Roche
 
Hussein Sweiti
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Patents, Royalties, Other Intellectual Property - FGFR Tyrosine Kinase Inhibitors For the Treatment Of Advanced Solid Tumors
 
Karen Xia
Employment - JJ Innovative Medicine
Stock and Other Ownership Interests - JJ Innovative Medicine
 
Saltanat Najmi
Employment - JJ Innovative Medicine
Stock and Other Ownership Interests - JJ Innovative Medicine
 
Constance Hammond
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Travel, Accommodations, Expenses - Johnson & Johnson/Janssen
 
Shibu Thomas
Employment - Janssen Research & Development
Leadership - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
Research Funding - Janssen Oncology
Patents, Royalties, Other Intellectual Property - 4 patents (Inst)
Travel, Accommodations, Expenses - Janssen Research & Development
 
Spyros Triantos
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Shubham Pant
Consulting or Advisory Role - Alligator Bioscience; AskGene Pharma; AstraZeneca; Boehringer Ingelheim; BPGbio; Ipsen; Janssen; Jazz Pharmaceuticals; Nihon Medi-Physics; Novartis; US WorldMeds; Zymeworks
Research Funding - 4D Pharma (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Immuneering (Inst); ImmunoMET (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)